Compare PKE & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PKE | NMRA |
|---|---|---|
| Founded | 1954 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.2M | 424.4M |
| IPO Year | N/A | 2023 |
| Metric | PKE | NMRA |
|---|---|---|
| Price | $24.57 | $2.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 296.4K | ★ 2.4M |
| Earning Date | 01-13-2026 | 03-02-2026 |
| Dividend Yield | ★ 1.98% | N/A |
| EPS Growth | ★ 19.30 | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $66,053,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $58.81 | ★ N/A |
| Revenue Growth | ★ 7.54 | N/A |
| 52 Week Low | $11.97 | $0.61 |
| 52 Week High | $26.12 | $3.25 |
| Indicator | PKE | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 59.73 | 51.18 |
| Support Level | $24.15 | $1.84 |
| Resistance Level | $26.00 | $2.18 |
| Average True Range (ATR) | 1.33 | 0.24 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 61.61 | 52.34 |
Park Aerospace Corp designs is an aerospace company which develops and manufactures solution and hot-melt composite materials used to produce composite structures for the aerospace markets. Its composite materials include film adhesives and lightning strike protection materials. Its composite materials are used to produce primary and secondary structures for jet engines, large and regional transport aircraft, military aircraft, Unmanned Aerial Vehicles (UAVs commonly referred to as drones), business jets, general aviation aircraft and rotary wing aircraft. The Company's products are sold to customers in North America, Asia and Europe.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.